BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Lin TJ, Lee HC, Lin CL, Wang CK, Chen KY, Wu DC. CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication. World J Clin Cases 2018; 6(12): 514-520 [PMID: 30397607 DOI: 10.12998/wjcc.v6.i12.514]
URL: https://www.wjgnet.com/2307-8960/full/v6/i12/514.htm
Number Citing Articles
1
Liem T. Nguyen, Vuong B. Nguyen, Tu V. Tran, Loan T. T. Le, Mai H. T. Phuong, Thang Nguyen. Effects of the EM CYP2C19 type and MDR1 3435CC gene on Helicobacter pylori eradication rate in patients with duodenal ulcer by the four-drug regimen of rabeprazole, bismuth, tetracycline, and tinidazolePharmacia 2024; 71: 1 doi: 10.3897/pharmacia.71.e108090
2
Azucena Arévalo Galvis, Alba Alicia Trespalacios Rangel, William Otero Regino. Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first‐line triple therapyHelicobacter 2019; 24(3) doi: 10.1111/hel.12574
3
Juan Fu, Chang-Feng Sun, Hong-Yan He, Suvash Chandra Ojha, Han Shi, Cun-Liang Deng, Yun-Jian Sheng. The Effect of CYP2C19 Gene Polymorphism on the Eradication Rate of Helicobacter Pylori by Proton Pump Inhibitors-ContAining Regimens in Asian Populations: a Meta-Analysis Pharmacogenomics 2021; 22(13): 859 doi: 10.2217/pgs-2020-0127
4
Danli Zhou, Wuyu Wang, Lan Gu, Meiling Han, Wujuan Hao, Junfeng Huang, Qiong Lin, Yan Wang. Helicobacter pylori antibiotic resistance profile in Chinese children with upper gastrointestinal symptoms and a literature review for developing personalized eradicating strategiesFrontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1392787
5
He-Jian Zhang, Xue-Hui Zhang, Jie Liu, Lu-Ning Sun, Yi-Wen Shen, Chen Zhou, Hong-Wen Zhang, Li-Jun Xie, Juan Chen, Yun Liu, Yong-Qing Wang. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitorsPharmacological Research 2020; 152: 104606 doi: 10.1016/j.phrs.2019.104606
6
Wen Gao, Hui Ye, Xin Deng, Chi Wang, Ying Xu, Yixuan Li, Xuezhi Zhang, Hong Cheng. Rabeprazole‐amoxicillin dual therapy as first‐line treatment for H pylori eradication in special patients: A retrospective, real‐life studyHelicobacter 2020; 25(5) doi: 10.1111/hel.12717